Asset Details
Do you wish to reserve the book?
Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity
Do you wish to request the book?
Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity
2025
Overview
Doxorubicin (Dox) is a widely used anti-cancer drug. It has proven efficacy against various cancers, although the clinical application of Dox has been limited due to dose-dependent, irreversible, and fatal Dox-induced cardiotoxicity (DIC). The mechanism of DIC remains unclear. p53 plays a key role in DIC via cardiomyocyte loss due to cell death and oxidative stress. Its expression is strictly controlled by post-translational modifications, and its suppression in cardiomyocytes reportedly ameliorates DIC. The ubiquitin system regulates biological processes that are fundamental to the development of cardiovascular diseases. The dysregulation of several ubiquitin E3 ligases is reportedly associated with DIC development through the upregulation of p53. Ubiquitin E3 ligases are classified into four groups; all classes of E3 ligases are involved in p53 degradation. In this review, we focus on recently emerging topics regarding the role of E3 ligases in the regulation of p53 degradation. We also provide an overview of the functional roles of E3 ligases in DIC. Recent reports have identified cardioprotective agents for DIC through ubiquitin E3 ligase-mediated p53 suppression. Here, we present some findings regarding the current development of cardioprotective agents for DIC. These agents may serve as a novel therapeutic target for the treatment of DIC.
Publisher
MDPI AG
Subject
/ Cancer
/ Cardiotoxicity - drug therapy
/ Doxorubicin - adverse effects
/ Enzymes
/ Genomes
/ Humans
/ Ligases
/ Lipids
/ Myocytes, Cardiac - drug effects
/ Myocytes, Cardiac - metabolism
/ Myocytes, Cardiac - pathology
/ Proteins
/ Tumor Suppressor Protein p53 - genetics
